OBJECTIVE： To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine （TCM）, on the janus kinase （JAK）/signal transducer and activator of transcription （STAT） pathway and matrix metalloproteinases ...OBJECTIVE： To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine （TCM）, on the janus kinase （JAK）/signal transducer and activator of transcription （STAT） pathway and matrix metalloproteinases （MMPs） in a chronic obstructive pulmonary disease （COPD） rat model with lung deficiency in terms of TCM＇s pattern differentiation. METHODS： Rats were randomly divided into a normal group, model group, Liuweibuqi group, Jinshuibao group, and spleen aminopeptidase group （n= 10）. Aside from the normal group, all rats were ex-posed to smoke plus lipopolysaccharide tracheal instillation to establish the COPD model with lung deficiency. Models were established after 28 days and then the normal and model groups were given normal saline （0.09 g/kg）, Liuweibuqi group was given Liuweibuqi capsule （0.35 g/kg）, Jinshuibao group was given Jinshuibao capsules （0.495 g/kg）, and the spleen group was given spleen aminopeptidase （0.33 mg/kg）, once a day for 30 days. Changes in symptoms, signs, and lung histology were observed. Lung function was measured with a spirometer. Serum cytokines were detected using enzyme-linked immunosorbent assay, and changes in the JAK/STAT pathway, MMP-9, and MMPs inhibitor 1 （TIMP1） were detected by immunohistochemistry, RT-PCR, and western blotting, respectively.RESULTS： Compared with the normal group, lung tissue was damaged, and lung function was reduced in the model control group. Additionally, the levels of interleukin （IL）-1β, y interferon （IFN-γ）, and IL-6 were higher, while IL-4 and IL-10 were lower in the model control group than those in the normal group. The expressions of JAK1, STAT3, ρ-STAT3, and MMP-9 mRNA and protein in lung tissue were higher, and TIMP1 mRNA and protein was lower in the model group compared with the normal group. After treatment, compared with the model group, the expression of inflammatory cytokines was lower in each treatment group, and expressions of JAK/ STAT pathway, MMPs were lower. Compared with the positive control groups, the Jinshuibao and spleen aminopeptidase groups, lung function was better, and JAK1, STAT3, and p-STAT3 protein were lower and TIMP1 was higher in the Liuweibuqi group.CONCLUSION： Liuweibuqi capsules can improve the symptoms of COPD possibly by regulating the expression of the JAK1/STAT3 pathway and MMP9/ TIMP1.展开更多
OBJECTIVE： To evaluate clinical efficacy of point application or adjuvant therapy on chronic obstruc- tive pulmonary disease in stationary phase and ef- fects on pulmonary functions. METHODS： Computer retrieved CNKI...OBJECTIVE： To evaluate clinical efficacy of point application or adjuvant therapy on chronic obstruc- tive pulmonary disease in stationary phase and ef- fects on pulmonary functions. METHODS： Computer retrieved CNKI, VIR CBM and other databanks and manual operations retrieved correlative literatures to find randomized con- trolled trials （RCTs） about comparison between point application or adjuvant therapy and no-point-applications for treatment of chronic ob- structive pulmonary disease in stationary phase in China. RevMan 5.0 software was used for Meta anal- ysis. RESULTS： Among 3481 cases in the inclusive 32 RCTS, 1780 cases were in the test group and 1701 cases in the control group. Meta analysis indicated： I） clinical efficacy： the groups containing point ap- plication therapy all were better than the groups ofno-point-application; 2） force vital capacity （FVC）： There was no statistically significant difference be- tween the group of point application plus Western Medicine and the Western Medicine group; 3） force expiratory volume 1 （FEVl）： The groups containing point application therapy were better than the no-point-application; 4） FEV1% ： the groups of point application plus Western Medicine were bet- ter than the Western Medicine groups; 5） FEVl/FVC： there was a significant difference between the group of point application plus Chinese drugs and the group of Chinese drug. CONCLUSION： Point application can increase clini- cal efficacy of chronic obstructive pulmonary dis- ease in stationary phase in varying degrees, and dif- ferent combinations of point application with Chi- nese drugs or Western Medicines have incomplete same actions in improvement of pulmonary func- tion and therapeutic effect.展开更多
OBJECTIVE： To evaluate the efficacy of Jianpi thera- py in Traditional Chinese Medicine （TCM） for treat- ment of chronic obstructive pulmonary disease （COPD） in stable phase by performing a systematic review and ...OBJECTIVE： To evaluate the efficacy of Jianpi thera- py in Traditional Chinese Medicine （TCM） for treat- ment of chronic obstructive pulmonary disease （COPD） in stable phase by performing a systematic review and meta-analysis. METHODS： The literatures concerning randomized controlled trials （RCTs） and quasi-RCTs comparing TCM treatment plus Western Medicine （WM） treat- ment with TCM alone, orTCM treatment vs no treatment, placebo for stable phase of COPD were searched in PubMed （1990-December 2010）, in Eng- lish and using Chinese National Knowledge Infra- structure （CNKI, 1990-December 2010）, Chinese Bio- medical Database （1990-December 2010）, Wang- fang Database （1990-December 2010）, and Weipu （VlP） Database in Chinese. The quality assessment and data extraction for RCTs were conducted by two reviewers independently. Jadad scale and allo-cation concealment were used to assess the quality of the included studies, and meta-analyses were conducted with the Collaboration＇s Revman 5.0 software. RESULTS： Seventeen RCTs or quasi-RCTs involving 1269 patients were included. The methodological quality was poor in all trials except one trial （Jadad score=4）. In the meta-analysis, TCM-WM treatment was significantly superior to WM treatment in cure rate [0R=3.82, 95%C/（2.45, 5.95）], and the effective rate between TCM treatment and placebo also had significant difference [0R=4.31, 95%C/（2.35, 7.91）]. Moreover, pulmonary function of the patients in TCM-WM group and TCM group was significantly improved [forced vital capacity （FVC）, P=O.01, quali- ty of life, P〈O.O01 ]. CONCLUSION： The experience in TCM-WM treat- ment of COPD in stable phase was encouraging. The current evidence shows that TCM-WM treat- ment might be more efficient in effective rate, qual- ity of life, and FVC than WM treatment alone. But for forced expiratory volume in one second （FEVl） and FEV1/FVC, no matter TCM-WM treatment com- pared with WM treatment alone or TCM treatment compared with placebo, there was no significant difference, with no obvious adverse reactions. Due to the low methodological quality of trials includ- ed, more RCTs of high quality in large scale are re- quired.展开更多
基金Supported by The National Natural Science Foundation Project:Study on the Metabolism of Chronic Obstructive Pulmonary Disease Pulmonary Qi Deficiency Syndrome and Cerebral Cortex Correlation Spectrum(No.81072781)
文摘OBJECTIVE： To observe effect of Liuweibuqi Capsule, a Traditional Chinese Medicine （TCM）, on the janus kinase （JAK）/signal transducer and activator of transcription （STAT） pathway and matrix metalloproteinases （MMPs） in a chronic obstructive pulmonary disease （COPD） rat model with lung deficiency in terms of TCM＇s pattern differentiation. METHODS： Rats were randomly divided into a normal group, model group, Liuweibuqi group, Jinshuibao group, and spleen aminopeptidase group （n= 10）. Aside from the normal group, all rats were ex-posed to smoke plus lipopolysaccharide tracheal instillation to establish the COPD model with lung deficiency. Models were established after 28 days and then the normal and model groups were given normal saline （0.09 g/kg）, Liuweibuqi group was given Liuweibuqi capsule （0.35 g/kg）, Jinshuibao group was given Jinshuibao capsules （0.495 g/kg）, and the spleen group was given spleen aminopeptidase （0.33 mg/kg）, once a day for 30 days. Changes in symptoms, signs, and lung histology were observed. Lung function was measured with a spirometer. Serum cytokines were detected using enzyme-linked immunosorbent assay, and changes in the JAK/STAT pathway, MMP-9, and MMPs inhibitor 1 （TIMP1） were detected by immunohistochemistry, RT-PCR, and western blotting, respectively.RESULTS： Compared with the normal group, lung tissue was damaged, and lung function was reduced in the model control group. Additionally, the levels of interleukin （IL）-1β, y interferon （IFN-γ）, and IL-6 were higher, while IL-4 and IL-10 were lower in the model control group than those in the normal group. The expressions of JAK1, STAT3, ρ-STAT3, and MMP-9 mRNA and protein in lung tissue were higher, and TIMP1 mRNA and protein was lower in the model group compared with the normal group. After treatment, compared with the model group, the expression of inflammatory cytokines was lower in each treatment group, and expressions of JAK/ STAT pathway, MMPs were lower. Compared with the positive control groups, the Jinshuibao and spleen aminopeptidase groups, lung function was better, and JAK1, STAT3, and p-STAT3 protein were lower and TIMP1 was higher in the Liuweibuqi group.CONCLUSION： Liuweibuqi capsules can improve the symptoms of COPD possibly by regulating the expression of the JAK1/STAT3 pathway and MMP9/ TIMP1.
文摘OBJECTIVE： To evaluate clinical efficacy of point application or adjuvant therapy on chronic obstruc- tive pulmonary disease in stationary phase and ef- fects on pulmonary functions. METHODS： Computer retrieved CNKI, VIR CBM and other databanks and manual operations retrieved correlative literatures to find randomized con- trolled trials （RCTs） about comparison between point application or adjuvant therapy and no-point-applications for treatment of chronic ob- structive pulmonary disease in stationary phase in China. RevMan 5.0 software was used for Meta anal- ysis. RESULTS： Among 3481 cases in the inclusive 32 RCTS, 1780 cases were in the test group and 1701 cases in the control group. Meta analysis indicated： I） clinical efficacy： the groups containing point ap- plication therapy all were better than the groups ofno-point-application; 2） force vital capacity （FVC）： There was no statistically significant difference be- tween the group of point application plus Western Medicine and the Western Medicine group; 3） force expiratory volume 1 （FEVl）： The groups containing point application therapy were better than the no-point-application; 4） FEV1% ： the groups of point application plus Western Medicine were bet- ter than the Western Medicine groups; 5） FEVl/FVC： there was a significant difference between the group of point application plus Chinese drugs and the group of Chinese drug. CONCLUSION： Point application can increase clini- cal efficacy of chronic obstructive pulmonary dis- ease in stationary phase in varying degrees, and dif- ferent combinations of point application with Chi- nese drugs or Western Medicines have incomplete same actions in improvement of pulmonary func- tion and therapeutic effect.
基金Supported by Program for Changjiang Scholars and Innovative Research Team in University, Ministry of Education ofChina (NO. IRT0977)
文摘OBJECTIVE： To evaluate the efficacy of Jianpi thera- py in Traditional Chinese Medicine （TCM） for treat- ment of chronic obstructive pulmonary disease （COPD） in stable phase by performing a systematic review and meta-analysis. METHODS： The literatures concerning randomized controlled trials （RCTs） and quasi-RCTs comparing TCM treatment plus Western Medicine （WM） treat- ment with TCM alone, orTCM treatment vs no treatment, placebo for stable phase of COPD were searched in PubMed （1990-December 2010）, in Eng- lish and using Chinese National Knowledge Infra- structure （CNKI, 1990-December 2010）, Chinese Bio- medical Database （1990-December 2010）, Wang- fang Database （1990-December 2010）, and Weipu （VlP） Database in Chinese. The quality assessment and data extraction for RCTs were conducted by two reviewers independently. Jadad scale and allo-cation concealment were used to assess the quality of the included studies, and meta-analyses were conducted with the Collaboration＇s Revman 5.0 software. RESULTS： Seventeen RCTs or quasi-RCTs involving 1269 patients were included. The methodological quality was poor in all trials except one trial （Jadad score=4）. In the meta-analysis, TCM-WM treatment was significantly superior to WM treatment in cure rate [0R=3.82, 95%C/（2.45, 5.95）], and the effective rate between TCM treatment and placebo also had significant difference [0R=4.31, 95%C/（2.35, 7.91）]. Moreover, pulmonary function of the patients in TCM-WM group and TCM group was significantly improved [forced vital capacity （FVC）, P=O.01, quali- ty of life, P〈O.O01 ]. CONCLUSION： The experience in TCM-WM treat- ment of COPD in stable phase was encouraging. The current evidence shows that TCM-WM treat- ment might be more efficient in effective rate, qual- ity of life, and FVC than WM treatment alone. But for forced expiratory volume in one second （FEVl） and FEV1/FVC, no matter TCM-WM treatment com- pared with WM treatment alone or TCM treatment compared with placebo, there was no significant difference, with no obvious adverse reactions. Due to the low methodological quality of trials includ- ed, more RCTs of high quality in large scale are re- quired.
